Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kojiro Tashiro

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
In Vivo (Athens, Greece)|February 26, 2025
Novel Preoperative Immune Prognostic Index for Predicting Outcomes in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaKen Shibata, Kosuke Iwatani, Y U Imai, et al.
International Journal of Clinical Oncology|December 9, 2025
Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumabMana Nakata, Fumihiko Urabe, Yu Imai, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Gastroenterology|August 10, 2020
Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and MetastasisAshutosh Tiwari, Kojiro Tashiro, Ajay Dixit, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Urologic Oncology|May 10, 2024
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective studyKatsuki Muramoto, Fumihiko Urabe, Yuhei Koike, et al.
Japanese Journal of Clinical Oncology|June 26, 2024
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomesShun Saito, Hidetsugu Takahashi, Yuji Yata, et al.
Japanese Journal of Clinical Oncology|August 30, 2023
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective studyKazuhiro Takahashi, Fumihiko Urabe, Yushi Suhara, et al.
Translational Andrology and Urology|December 19, 2024
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort studyRyotaro Yamaguchi, Hirokazu Kagawa, Kentaro Yoshihara, et al.
Translational Andrology and Urology|April 9, 2024
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective studyNaoki Uchida, Fumihiko Urabe, Yushi Suhara, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
In Vivo (Athens, Greece)|February 26, 2025
Novel Preoperative Immune Prognostic Index for Predicting Outcomes in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaKen Shibata, Kosuke Iwatani, Y U Imai, et al.
International Journal of Clinical Oncology|December 9, 2025
Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumabMana Nakata, Fumihiko Urabe, Yu Imai, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Gastroenterology|August 10, 2020
Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and MetastasisAshutosh Tiwari, Kojiro Tashiro, Ajay Dixit, et al.
Japanese Journal of Clinical Oncology|July 22, 2024
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Yu Imai, Yuma Goto, et al.
Urologic Oncology|May 10, 2024
Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective studyKatsuki Muramoto, Fumihiko Urabe, Yuhei Koike, et al.
Japanese Journal of Clinical Oncology|June 26, 2024
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomesShun Saito, Hidetsugu Takahashi, Yuji Yata, et al.
Japanese Journal of Clinical Oncology|August 30, 2023
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective studyKazuhiro Takahashi, Fumihiko Urabe, Yushi Suhara, et al.
Translational Andrology and Urology|December 19, 2024
Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort studyRyotaro Yamaguchi, Hirokazu Kagawa, Kentaro Yoshihara, et al.
Translational Andrology and Urology|April 9, 2024
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective studyNaoki Uchida, Fumihiko Urabe, Yushi Suhara, et al.
Pageof 10